
==== Front
Cancer Med
Cancer Med
10.1002/(ISSN)2045-7634
CAM4
Cancer Medicine
2045-7634
John Wiley and Sons Inc. Hoboken

10.1002/cam4.70214
CAM470214
Correction
Correction
Correction to “Comprehensive analysis of clinical prognosis and biological significance of CNIH4 in cervical cancer”Wang J, Wang S, Wang J, Huang J, Lu H, Pan B, Pan H, Song Y, Deng Q, Jin X, Shi G. Comprehensive analysis of clinical prognosis and biological significance of CNIH4 in cervical cancer. Cancer Med. 2023;12(24):22381–22394. doi: 10.1002/cam4.6734
08 9 2024
9 2024
08 9 2024
13 17 10.1002/cam4.v13.17 e70214© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

10.1002/cam4.6734 source-schema-version-number2.0
cover-dateSeptember 2024
details-of-publishers-convertorConverter:WILEY_ML3GV2_TO_JATSPMC version:6.4.8 mode:remove_FC converted:09.09.2024
==== Body
pmcIn section 2.7 on page 22383, “Tubulin (1:20000, Proteintech)” should have read “Actin (1:80000, ABclonal).” In Figure 3, Part A, on page 22388, “Tubulin” was incorrect and should have read “Actin.” Please see the corrected figure below. Although we used both Actin and Tubulin as the internal reference genes in the pre‐experiment, the statistics of the data show Actin instead of Tubulin.

Figure 3  

We apologize for these errors.
